Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Treace Medical Concepts, Inc. in the offering. Treace Medical Concepts, Inc. (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Biomea Fusion, Inc. in the transaction. Biomea Fusion, Inc. (Nasdaq: BMEA) closed its initial public offering of 9 million shares of its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Design Therapeutics, Inc. Design Therapeutics, Inc. executed its initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Maples and Calder represented Connect Biopharma in the transaction. Global Law Office and Davis Polk advised joint book-running managers. Connect Biopharma...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Chardan Healthcare Acquisition 2 Corp. in the transaction. Renovacor, Inc. (Renovacor), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented an affiliate of Baring Private Equity Asia in the transaction, while Yigal Arnon & Co. and Latham & Watkins represented Boston Scientific,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP advised Owlet Baby Care, while Ropes & Gray LLP advised Sandbridge on the deal. Owlet Baby Care Inc. and Sandbridge Acquisition Corporation...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Angion in the offering and private placement. Angion Biomedica Corp. (NASDAQ:ANGN) has announced the pricing of its initial public offering of 5...
You must be a Standard 1 Year member to access this content.
